of 43 patients with EGFR-mutated NSCLC with BM treated with erlotinib or gefitinib demonstrating an icORR of 57% and intracranial disease control rate (icDCR) of 91% (38). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.